For decades, America’s drug-price debate has centered on a fundamental tension: How do policymakers encourage expensive research and development, while ensuring that companies keep final prices ...

More than 100 days into President Donald Trump’s second term, the administration has fallen into a pattern. Trump releases an executive order with an expansive title accompanied by even more expansive ...

What Did Conservatives Conserve Before 1955? Audio By Carbonatix Health and Human Services Secretary Robert F. Kennedy Jr., at a White House event to announce President Trump’s new ...

The high cost of prescription drugs in America has again moved back into the political spotlight, with President Trump recently signing an executive order aimed at bringing prices more in line with ...

President Trump proposed a plan to lower prescription drug prices, focusing on the "Most Favored Nation" executive order. The plan aims to address the disparity in drug prices between the U.S. and ...

In an executive order last week, President Donald Trump effectively instituted price controls on prescription drugs—not just those purchased by the government through Medicare and Medicaid, but ...

One can desire lower-cost access to drugs while being troubled by President Trump's executive order (EO) last week. Critics argue that the EO imports bad policies that are in effect in the rest of the ...

A new report indicates that U.S. drugmakers will raise prices on at least 350 medications despite pressure from President ...

President Donald Trump is right that Americans pay too high a price for many pharmaceuticals. In a May 12 speech and signing of an executive order aimed at rectifying the problem, Trump correctly ...

The Trump administration recently released an executive order directing Medicare and Medicaid drug reimbursement to be based on prices in other countries, using a model called Most Favored Nation (MFN ...

After Donald Trump signed an executive order slashing drug prices last week, experts have highlighted how pharmacy benefit managers (PBMs) could be hit the hardest despite pharmaceutical companies ...